SPONSOR
Beijing Biotech
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 2, Phase 1
Conditions studied: Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CarcinomaRecurrent or Refractory Disease After Standard TherapiesRecurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCCPancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic DiseaseMalignant GliomaHigh-Grade Gliomas
Beijing Biotech is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing Biotech
How many clinical trials has Beijing Biotech sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Beijing Biotech, of which 6 are actively recruiting participants. These trials cover conditions including Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing Biotech research focus on?
Beijing Biotech clinical trials span Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing Biotech clinical trial?
To participate in a Beijing Biotech trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing Biotech trials with current recruitment status updated daily.
Clinical Trials by Beijing Biotech
NCT07617753 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Epithelial Ovarian Cancer
NCT07617805 Phase 1, Phase 2
Recruiting
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT07480928 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07551336 Phase 1
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Malignant Glioma
NCT07523555 Phase 1, Phase 2
Recruiting
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07480954 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Epithelial Ovarian Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology